Akash Tewari
Stock Analyst at Jefferies
(2.40)
# 2,534
Out of 5,241 analysts
62
Total ratings
41.67%
Success rate
2.57%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Buy | $47 → $85 | $70.08 | +21.29% | 2 | Apr 13, 2026 | |
| BNTX BioNTech SE | Maintains: Buy | $151 → $138 | $88.85 | +55.32% | 4 | Mar 10, 2026 | |
| VRTX Vertex Pharmaceuticals | Initiates: Buy | $580 | $436.58 | +32.85% | 1 | Mar 10, 2026 | |
| AMGN Amgen | Initiates: Hold | $350 | $324.39 | +7.89% | 1 | Mar 10, 2026 | |
| GILD Gilead Sciences | Initiates: Buy | $180 | $129.67 | +38.81% | 1 | Mar 10, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $83 → $96 | $72.52 | +32.38% | 2 | Sep 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $813 → $831 | $629.68 | +31.97% | 5 | Aug 27, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $26 | $18.55 | +40.16% | 1 | Aug 25, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $8.78 | +13.90% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $57.31 | +18.65% | 4 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $49.67 | +91.26% | 2 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 → $16 | $12.10 | +32.23% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $177 → $189 | $157.21 | +20.22% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $994 → $1,015 | $988.09 | +2.72% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $37.19 | +34.44% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $78.75 | -4.76% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $25.33 | +53.97% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $13.45 | +33.83% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $776.26 | -33.91% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $112.56 | +11.05% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $24.43 | -54.97% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.65 | +930.30% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $75.18 | -0.24% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $522.23 | -71.09% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $49.84 | -43.82% | 3 | Oct 7, 2021 |
Spyre Therapeutics
Apr 13, 2026
Maintains: Buy
Price Target: $47 → $85
Current: $70.08
Upside: +21.29%
BioNTech SE
Mar 10, 2026
Maintains: Buy
Price Target: $151 → $138
Current: $88.85
Upside: +55.32%
Vertex Pharmaceuticals
Mar 10, 2026
Initiates: Buy
Price Target: $580
Current: $436.58
Upside: +32.85%
Amgen
Mar 10, 2026
Initiates: Hold
Price Target: $350
Current: $324.39
Upside: +7.89%
Gilead Sciences
Mar 10, 2026
Initiates: Buy
Price Target: $180
Current: $129.67
Upside: +38.81%
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $83 → $96
Current: $72.52
Upside: +32.38%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Buy
Price Target: $813 → $831
Current: $629.68
Upside: +31.97%
Crescent Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $26
Current: $18.55
Upside: +40.16%
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $8.78
Upside: +13.90%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $57.31
Upside: +18.65%
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $49.67
Upside: +91.26%
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $12.10
Upside: +32.23%
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $157.21
Upside: +20.22%
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $988.09
Upside: +2.72%
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $37.19
Upside: +34.44%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $78.75
Upside: -4.76%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $25.33
Upside: +53.97%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $13.45
Upside: +33.83%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $776.26
Upside: -33.91%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $112.56
Upside: +11.05%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $24.43
Upside: -54.97%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.65
Upside: +930.30%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $75.18
Upside: -0.24%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $522.23
Upside: -71.09%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $49.84
Upside: -43.82%